Status:
UNKNOWN
Non-Eosinophilic Biological Effects of IL-5
Lead Sponsor:
Imperial College London
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with ast...
Detailed Description
IL-5 has been shown to be present in higher levels in those with asthma, more so during viral infection. The investigators know from existing evidence that having increased levels of interferon (IFN) ...
Eligibility Criteria
Inclusion
- Must be eligible for the study 'Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma' (MAELABA) (19SM5101).
Exclusion
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT06026202
Start Date
September 1 2023
End Date
September 30 2024
Last Update
October 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College London
London, United Kingdom, W2 1NY